Izilendustat hydrochloride 

Izilendustat hydrochloride is a potent prolyl hydroxylase inhibitor. Izilendustat hydrochloride competitively inhibits HIFPH2 activity, blocks HIF-1α degradation, stabilizes HIF-1α and HIF-2α proteins, and upregulates downstream target gene expression. Izilendustat hydrochloride can reduce intestinal inflammation and damage, enhance the ability of phagocytes to clear pathogens, and improve ischemia-related pathological phenotypes. Izilendustat hydrochloride can be used for the research of inflammatory bowel disease, ischemic vascular disease and anemia^[1][2].

prolyl hydroxylase^[1]

Izilendustat (Compound A41) (1.2 μM) hydrochloride inhibits HIFPH2 (EGLN1) activity in enzymatic assays^[1].
Izilendustat (Compound A41) (1-50 μM; 7 h) hydrochloride upregulates PGK and VEGF expression in wild-type MEFs but not in HIF-1α knockout MEFs^[2].
Izilendustat (10 μM) hydrochloride enhances bacterial clearance in U937 cells infected with S. aureus (Newman or MRSA strain)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Izilendustat (Compound A41) (0.3-5 mg/kg; s.c.; once daily) hydrochloride prevents body weight loss, ameliorates colon shortening, reduces disease activity scores, decreases mesenteric lymph node leukocyte count and maintains hematocrit levels in TNBS-induced colitis mice^[1].
Izilendustat (5-10 mg/kg; s.c.; every other day) hydrochloride enhances the antitumor effect of 5-Fluorouracil (HY-90006) in mouse colon 26 carcinoma xenograft models^[1].
Izilendustat (Compound A41) (0.5-10 mg/kg; p.o./s.c.; once daily) hydrochloride reduces skin lesion size and bacterial load in S. aureus- and S. pyogenes-infected mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

470.39

C₂₂H₂₉Cl₂N₃O₄

1303513-80-5

O=C(N1CCN(CC(C=CN2CC3=CC=C(Cl)C=C3)=C(O)C2=O)CC1)OC(C)(C)C.[H]Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gardner JH, Shalwitz R. Prolyl hydroxylase inhibitors. WO, WO2011057115A1. 2011-05-12.

  [2]. Gardner JH, Shalwitz R. Compositions and methods for treating colitis. WO, WO2011057121A1. 2011-05-12.